Royalty Report: Medical, Device, Therapeutic – Collection: 372635

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 12

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 12

Primary Industries

  • Medical
  • Device
  • Therapeutic
  • Nerve
  • Health & Fitness
  • Drugs
  • Pharmaceuticals
  • Electro Medical/ Elector therapeutic
  • Pain

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 372635

License Grant
Licensor grants Licensee an exclusive worldwide license for the Field of Use under the Licensed Patents and Licensed Know-How to make, have made for, use, have used for, sell, have sold for, offer to sell, import and/or otherwise dispose of Products, to practice, have practiced for, teach and have taught for Licensed Methods, and to otherwise commercially exploit the Licensed Know-How and the technology disclosed in the Licensed Patents and Licensed Know-How.
License Property
“Licensed Patent(s)” are the Licensed Cyberonics Patent(s) and the Licensed Roslin Patents.

Cyberonics Patents
5,188,104  Treatment of Eating Disorders by Nerve Stimulation
5,231,988 Treatment of Endocrine Disorders by Nerve Stimulation
5,263,480 Treatment of Eating Disorders by Nerve Stimulation
5,540,730 Treatment of Motility Disorders by Nerve Stimulation
5,540,734 Cranial Nerve Stimulation Treatments Using Neurocybernetic Prosthesis
5,707,400 Treating Refractory Hypertension by Nerve Stimulation
20060247719 Weight Loss Method and Device
20060247721 Identification of Electrodes for Nerve Stimulation in the Treatment of Eating Disorders
20060247722 Noninvasively Adjustable Gastric Band
20070027483 Stimulating Cranial Nerve to Treat Disorders Associated with the Thyroid Gland
20070027484 Autonomic Nerve Stimulation to Treat a Pancreatic Disorder
20070027492 Autonomic Nerve Stimulation to Treat a Gastrointestinal Disorder
20070027498 Selective Nerve Stimulation for the Treatment of Eating Disorders
20070093870 Cranial Nerve Stimulation to Treat Eating Disorders

Roslin Patents
6,587,719  Treatment of Obesity by Bilateral Vagus Nerve Stimulation
6,609,025  Treatment of Obesity by Sub-Diaphragmatic Nerve Stimulation
7,299,091  Treatment of Obesity by Bilateral Vagus Nerve Stimulation
20040039427  Treatment of Obesity by Sub-Diaphragmatic Nerve Stimulation

Field of Use
Licensee has the rights to ther patents and patent applications to use vagus nerve stimulation for the treatment of obesity and two related co-morbidities, diabetes and hypertension, in overweight patients.

“Field of Use” shall mean the treatment (including therapeutic or diagnostic) by means of a device that applies electrical signals directly or indirectly to the vagus, trigeminal or glossopharyngeal nerves i) for weight reduction, or ii) for hypertension or diabetes (including impaired fasting glycaemia, impaired glucose tolerance or insulin resistance) in patients having a body mass index of 25 or more.

IPSCIO Record ID: 275818

License Grant
Licensor grants a non-transferable, exclusive, worldwide license or sublicense, under the Licensed Patents and Licensed Know-How, to practice and otherwise exploit the same in the Field only, to make, have made, use, sell, offer to sell, and/or import Licensed Products & Methods.
License Property
The property is certain technology to stimulate the vagus nerve.

The vagus nerve, historically cited as the pneumogastric nerve, is the tenth cranial nerve or CN X, and interfaces with the parasympathetic control of the heart, lungs, and digestive tract. The vagus nerves are paired but are normally referred to in the singular.

Licensed Patents means the NS, the Feinstein Institute for Medical Research, formerly known as North Shore Long Island Jewish Research Institute licensed Patents.

The patents include Inhibition of Inflammatory Cytokine Production by Stimulation of Brain Muscarinic Receptors, and, Cholinergic Agonists and Vagus Nerve Stimulation, and, Neural Tourniquet.

Field of Use
The Field means vagal nerve stimulation by any means. Exemplary vagal nerve stimulation modalities within the Field include mechanical (such as massage, needle, acoustic or other vibrational), electrical, thermal, magnetic, and electromagnetic, or as produced by any other energy source.

Vagus nerve stimulation is a medical treatment that involves delivering electrical impulses to the vagus nerve. It is used as an add-on treatment for certain types of intractable epilepsy and treatment-resistant depression. Frequent side effects include coughing and shortness of breath.

IPSCIO Record ID: 375

License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts from Licensor, upon the terms and conditions herein after specified, the exclusive, worldwide right and license under the Licensed Patents and Technology to further test and develop the Technology, to make, to have made, to use, to sell, to lease, to implant, and to have implanted and otherwise dispose of Products and to sublicense the rights created hereby pursuant to the terms.
License Property
Technology relates to a patent for Neurocyberenetic Prosthesis Technology.  This license agreement covers the method and devices of the neurocybernetic prosthesis ('NCP') System for vagus nerve and other cranial nerve stimulation for the control of epilepsy and other movement disorders.  The NCP system is an implantable, multiprogrammable pulse generator that delivers constant current electrical signals to the vagus nerve for the purpose of reducing the frequency and severity of epileptic seizures. The signals are delivered on a predetermined schedule, or may be initiated by the patient with an external magnet. The device is implanted in a subcutaneous pocket in the chest just below the clavicle, similar to pacemaker placement. The stimulation signal is transmitted from the prosthesis to the vagus nerve through a lead connected to an electrode which is a multi-turn silicone helix, with a platinum band on the inner turn of one helix. The prosthesis can be programmed with any IBM- compatible personal computer using NCP software and a programming wand.

Licensor owns a patent relating to Neurocyberenetic Prosthesis Technology (U.S. Patent No. 4,702,254) and other pending patent applications and know-how, and technology relating thereto (collectively referred to as the “Technology”).

4,702,254

US

NeuroCybernetic Prosthesis

Oct. 27, 1987

4,867,164

US

NeuroCybernetic Prosthesis

Sept. 19, 1989

50,258,807

US

NeuroCybernetic Prosthesis

June 25, 1991

577,549

Australia

NeuroCybernetic Prosthesis

March 3, 1989
1,259,379

Canada

NeuroCybernetic Prosthesis

September 12, 1989
0,156,854

Eurpoean

NeuroCybernetic Prosthesis

September 5, 1990

Austria, Belgium, Switzerland, Germany, France, United

Kingdom, Liechtenstein, Luxembourg, Netherlands, Sweden

503,504/84

Japan

Application Number

September 11, 1984

Field of Use
NCP System is an implantable medical device for the treatment of epilepsy.

IPSCIO Record ID: 3613

License Grant
Licensor, an individual, agrees to grant to Licensee the exclusive worldwide right and license to all of Licensor's rights in and to the Licensed Patents, including but not limited to the exclusive worldwide right and license to make, have made, use, sell, import, export and otherwise dispose of the Licensed Products, and to practice the Licensed Methods.  This will also include the right to grant sublicenses to third parties.
License Property
Licensed Patents are for Treatment of Obesity by Bilateral Vagus Nerve Stimulation.
Field of Use
Licensee is engaged in designing, developing, investigating, testing, and marketing specialized medical devices primarily used or to be used for treating disorders by nervous system stimulation.

IPSCIO Record ID: 4588

License Grant
Pursuant to the licensing agreement, as amended, the University granted a worldwide exclusive license under certain patents and patent applications generally relating to transcutaneous and subcutaneous bilateral neurostimulation for the treatment of neuropsychiatric and neurological disorders. The Licensee is obligated to use commercially reasonable efforts to develop and commercialize one or more licensed products, and thereafter make licensed products reasonably available to the public.
License Property
The license primarily relates to treatments for major neurological and neuropsychiatric disorders such as epilepsy, depression, attention deficit disorder, and post-traumatic stress disorder and to stents.

The present disclosure relates to methods, devices, and systems used for the treatment of mood, anxiety, cognitive, and behavioral disorders (collectively, neuropsychiatric disorders) via stimulation of the superficial elements of the trigeminal nerve (“TNS”). More specifically, minimally invasive systems, devices and methods of stimulation of the superficial branches of the trigeminal nerve located extracranially in the face, namely the supraorbital, supratrochlear, infraorbital, auriculotemporal, zygomaticotemporal, zygomaticoorbital, zygomaticofacial, nasal and mentalis nerves (also referred to collectively as the superficial trigeminal nerve) are disclosed herein.

The present disclosure generally relates to implantable neurostimulator systems, devices and methods of using the same and more particularly relates to implantable neurostimulator systems, devices and methods including at least one implantable electrode for treating neuropsychiatric disorders by stimulating superficial, cutaneous elements of cranial nerve(s).

IPSCIO Record ID: 4554

License Grant
The Licensor hereby grants to the Licensee and its Affiliates a worldwide, exclusive license to make, have made, use, lease and sell Devices, and components and parts utilizing the Patent Rights for the purpose of advancing the theory, application and commercialization of induced neuroplasticity devices.
License Property
Patent Rights shall mean U.S. Patent Application 12/348301 and Provisional Patent Application 61/019,061.

The intellectual property relates to the PoNSTM device. The Patent Rights include one XYZ claim and 22 method claims, which cover a device in the form of a mouth piece that non-invasively delivers neurostimulation to the brain stem via the trigeminal nerve.

The intellectual property relating to the PoNSTM device is the subject of U.S. Patent Application 12/348301 and Provisional Patent Application 61/019,061. (Information on the patent applications was not available from the U.S. Patent and Trademark office.)

The device is held lightly in place by the lips and teeth around the neck of the tab that goes into the mouth and rests on the anterior, superior part of the tongue. The paddle-shaped tab of the device has a hexagonally patterned array of 143 gold-plated circular electrodes (1.50 mm diameter, on 2.34 mm centers) that is created by a photolithographic process used to make printed circuit boards. It uses low-level electrical current to stimulate the lingual branch projections of at least two cranial nerves in the anterior tongue through the gold-plated electrodes.

The brain's ability to recognize its operation in response to new information sources, new functional needs, or new communication pathways is referred to as neuroplasticity. Neuroplasticity is a process underlying all cerebral learning, training, and rehabilitation. Neuromodulation is the use of external tactile stimulation to intentionally change and regulate the internal electrochemical environment of the brain.  Traditional rehabilitation interventions have typically involved medication and various forms of therapies, including physical therapy. The PoNSTM device is being investigated in combination with physical therapy for the treatment of neurological symptoms from disease and trauma including traumatic brain injury (TBI) and Multiple Sclerosis.  The patent is pending on the device.

Field of Use
The Licensee is a company formed for the purpose of advancing the theory, application and commercialization of induced neuroplasticity devices to persons with sensory and neurological needs.

IPSCIO Record ID: 250719

License Grant
Foundation hereby grants to Licensee royalty-bearing, license, with the right to sublicense to make, have made, lease, offer to lease, use, sell, offer for sale, market, promote, advertise, import, research, develop and commercialize Licensed Products in the Field only, in the Territory; provided that with respect to Externals, the foregoing license shall only apply to the extent that such Externals are used in connection with the foregoing licensed activities involving Licensed Products other than Externals.
License Property
“Licensed Product” means (i) Epione and (ii) all Externals sold or distributed solely for use with Epione.

Licensed Products are worldwide for the treatment of (i) chronic pain in humans through the application of electrical energy to the nervous system, (ii) inflammatory conditions of the human body through the application of electrical energy to the vagus nerve, a nerve that interfaces with parasympathetic control of the heart, lungs and digestive tract and (iii) urinary and fecal dysfunction in humans through the application of electrical energy anywhere in or on the human body, excluding, in each case, any product or method that involves the placement of electrodes or the administration of electrical stimulation inside the cranial cavity or to the ocular nervous system or the auditory nervous system.

“Epione” means the Epione implantable pulse generator, leads, external pulse generator, charging system and related system components and software

“Externals” means any peripheral or auxiliary device that can be used in connection with, or operate in concert with, Epione, including the components that when assembled comprise such device, and including surgical procedure tools, protection apparatus, controllers, battery chargers, patient remote controller, programmer, software and electrodes.

Field of Use
“Initial Field” means (i) the treatment of chronic pain in humans through the application of electrical energy to the nervous system; and (ii) the treatment of inflammatory conditions of the human body through the application of electrical energy to the vagus nerve.

IPSCIO Record ID: 27500

License Grant
The University's hereby grants to Licensee an exclusive license under the University's Patent Rights, in jurisdictions where the University's Patent Rights exist, to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law. Licensee will not make, use, have made, sell, offer for sale, or import Licensed Products outside the Field of Use.

The University's hereby grants to Licensee a non-exclusive license (the 'Copyright License') under Regents' Copyright Rights, in jurisdictions where the University's Copyright Rights exist, to use, produce, copy, reproduce, display, create derivative works of, perform, and distribute the Licensed Copyright Products in the Field of Use to the extent permitted by law.

The University's grants to Licensee the right to sublicense the University's Patent Rights granted to Licensee.

License Property
Technology refers to licensed products and to practice licensed methods to treat pain from headaches, migraines, trigeminal neuralgia or neuropathic disorders of the head and mouth. The agreement also includes a non-exclusive license to the copyright over certain user interface software for controlling and monitoring nerve stimulation.

Head Pain Management. The other innovation consists of technology designed to take advantage of the fact that stimulating the sensory fibers of a nerve can mask pain perception. The technology uses mechanical vibration (as opposed to electrical stimulation) to stimulate such fibers and is non-invasive and patient controllable. The target market for the commercialization of this technology would include migraine sufferers; those with trigeminal neuropathy, a debilitating, long-lasting oral pain, often arising from failed or compromised dental procedures; and others.

Provisional Patent Application No. 61/905,616 entitled, 'Device, System and Method for Reducing Headache Pain,' filed November 18th, 2013

“Copyright Graphical User Interface Software to Control and Monitor Nerve Stimulation Device'

Field of Use
'Field of Use' means treatment of pain from headaches, migraines, trigeminal neuralgia, or neuropathic disorders of the head and mouth.

IPSCIO Record ID: 384872

License Grant
Under the terms of the Termination Agreement, Licensor transferred back to Licensee all of Licensors rights in the Quell technology related to markets outside the United States, including technology improvements and intellectual property.
License Property
Quell is a wearable technology for chronic pain, designed to address many of the limitations of traditional TENS. It incorporates a collection of proprietary approaches designed to optimize the effectiveness of nerve stimulation. These include high power electrical stimulation hardware with precise control, algorithms that automatically determine therapeutic stimulation intensity and compensate for nerve desensitization, and automated detection of user sleep and appropriate adjustment of stimulation level. Quell is comprised of (1) an electronic device that is placed in a flexible band worn on the upper calf, (2) an electrode that attaches to the device and is the interface between the device and the skin, and (3) a smartphone app to control the device and visualize, understand and optimize data relating to chronic pain and health. The app is integrated with the Quell Health Cloud for storage of user data, data analytics and scientific research. An Apple Watch® app provides many of the functions of the smartphone app with the convenience of a smartwatch. The Quell device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for symptomatic relief and management of chronic pain and is available OTC via e-commerce.

Transcutaneous electrical nerve stimulation (TENS) is a Non-invasive approach achieving limited efficacy in practice due to power limitations, inadequate dosing and low patient adherence.

Field of Use
The rights granted are for a device used to manage chronic pain of the lower extremity.

IPSCIO Record ID: 26559

License Grant
Licensor hereby appoints and grants to Licensee, and Licensee hereby accepts from Licensor, the exclusive right and license to use, manufacture, market, sell and distribute the Products during the term of this Agreement, upon the terms and conditions contained herein.
License Property
Licensor is a medical device company that develops products for patients in the urogynecology and gynecology markets and has developed, and continues to develop, neurostimulation devices currently being, or proposed to be, marketed under the brand names and trademarks (collectively, the Trademarks) Urgent®, Urgent-PC™ and Urgent-SQ™ (collectively as now existing or hereafter improved, modified or enhanced, the Products).

The Urgent PC Neuromodulation System uses percutaneous tibial nerve stimulation (PTNS) to treat overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence.

The Urgent PC neuromodulation system is a minimally invasive device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. This product uses percutaneous tibial nerve stimulation to deliver an electrical pulse that travels to the sacral nerve plexus, a control center for bladder function.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 28986

License Grant
The University hereby grants to Licensee an exclusive license under the University's Patent Rights, in jurisdictions where the University's Patent Rights exist, to make, have made, use, sell, offer for sale and import Licensed Products and to practice Licensed Methods in the Field of Use to the extent permitted by law. Licensee will not make, use, have made, sell, offer for sale, or import Licensed Products outside the Field of Use.

The agreement also includes a non-exclusive license to the copyright over certain user interface software for controlling and monitoring nerve stimulation. The agreement allows for sublicensing.

License Property
Licensed products and to practice licensed methods for treatment of conditions related to sleep-disordered breathing, including sleep apnea, congenital central hypoventilation syndrome and the improvement of sleep quality.

Sleep Disorders. One innovation consists of technology designed to take advantage of the fact that signals from the limbs interpreted by the brain as movement can elicit enhanced breathing rates. The device we would expect to develop would use a nerve stimulation technique to enhance the breathing rate without actual limb movement. The target market for the commercialization of this technology would include people who suffer sleep disorders mostly due to irregular breathing, the most common of which is sleep apnea.

Provisional Patent Application No. 61/856,883 entitled, 'Device, System and Method for Facilitating Breathing Via Stimulation of Limb Movement'

Patent Cooperation Treaty Application No. PCT/US14/047642 entitled, 'Device, System and Method for Facilitating Breathing Via Simulation of Limb Movement'

“Copyright Graphical User Interface Software to Control and Monitor Nerve Stimulation Device'

Field of Use
'Field of Use' means treatment of conditions related to sleep-disordered breathing (including sleep apnea, congenital central hypoventilation syndrome (CCHS), or primary alveolar hypoventilation) and for improvement of sleep quality.

IPSCIO Record ID: 275838

License Grant
The Foundation, nonprofit foundation of an University,  grants, and Licensee accepts, an exclusive license to the Licensed Patents and Licensed IP to develop, make, have made, use, and sell Licensed Products on a royalty-bearing basis in the Field of Use in the Licensed Territory and for issuance of corresponding Sublicenses directly between Licensee and a Sublicensee.
License Property
Technology
Oscillating Field Stimulation (OFS)
Oscillating Field Stimulation and a Growth Factor
4-AP Derivatives
Hydralazine
Hydralazine + PEG
PEG for Vascular Leakage
Double Sucrose Gap Recording Apparatus
Coherent Anti-Stokes Raman Scattering

Licensed Patents shall mean
4,919,140 – Method and apparatus for regenerating nerves

OFS + Inosine Technology means the technology  No 62139, US Patent Application No. 10/748,572 and /or PT Patent Application No. PCT/US2003/01480.

Field of Use
Field of Use shall mean human and veterinary therapeutics.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.